{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-064739","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.163631+00:00","generated_at":"2026-06-14T14:27:51.047128+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Leap Therapeutics reports 19.5-month median OS from DKN-01 combo in gastric cancer; data at ASCO 2023","bullets":["Median OS 19.5 months, median PFS 11.3 months in first-line GEA patients (n=25), exceeding current benchmarks.","ORR 73% in mITT population; 86% ORR in PD-L1-low patients; 90% ORR in DKK1-high patients.","Additional partial response after 22 months of therapy; tumor reductions deepen over time.","Part C randomized controlled trial enrolling; completion expected late 2023; colorectal data coming."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-064739","json":"https://secwatch.observer/filing/0001104659-23-064739.json","markdown":"https://secwatch.observer/filing/0001104659-23-064739.md","text":"https://secwatch.observer/filing/0001104659-23-064739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923064739/0001104659-23-064739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923064739/tm2317022d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T14:27:51.047128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}